Cambium Bio (ASX:CMB) Days Payable : 0.00 (As of Dec. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Cambium Bio Days Payable?

Cambium Bio's average Accounts Payable for the six months ended in Dec. 2023 was A$0.63 Mil. Cambium Bio's Cost of Goods Sold for the six months ended in Dec. 2023 was A$0.00 Mil.

The historical rank and industry rank for Cambium Bio's Days Payable or its related term are showing as below:

During the past 11 years, Cambium Bio's highest Days Payable was 2949.86. The lowest was 177.11. And the median was 622.13.

ASX:CMB's Days Payable is not ranked ^*
in the Biotechnology industry.
Industry Median: 135.18
* Ranked among companies with meaningful Days Payable only.

Cambium Bio's Days Payable stayed the same from Dec. 2022 (0.00) to Dec. 2023 (0.00).

Cambium Bio Days Payable Historical Data

The historical data trend for Cambium Bio's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cambium Bio Days Payable Chart

Cambium Bio Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Days Payable

Get a 7-Day Free Trial

Cambium Bio Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Days Payable	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Cambium Bio's Days Payable

For the Biotechnology subindustry, Cambium Bio's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cambium Bio's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cambium Bio's Days Payable distribution charts can be found below:

* The bar in red indicates where Cambium Bio's Days Payable falls into.

Cambium Bio Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Cambium Bio's Days Payable for the fiscal year that ended in Jun. 2024 is calculated as

	Days Payable (A: Jun. 2024 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Jun. 2023 )	+	Accounts Payable (A: Jun. 2024 ))	/	count )	/	Cost of Goods Sold (A: Jun. 2024 )	*	Days in Period
=	( (0.256	+	1.221)	/	2 )	/	0	*	365
=	0.7385					/	0	*	365
=	N/A

Cambium Bio's Days Payable for the quarter that ended in Dec. 2023 is calculated as:

	Days Payable (Q: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Jun. 2023 )	+	Accounts Payable (Q: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (Q: Dec. 2023 )	*	Days in Period
=	( (0.256	+	1)	/	2 )	/	0	*	365 / 2
=	0.628					/	0	*	365 / 2
=	N/A

Cambium Bio Days Payable Related Terms

Thank you for viewing the detailed overview of Cambium Bio's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Cambium Bio Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cambium Bio Ltd (ASX:CMB) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

N/A

Address

16 Goodhope Street, Paddington, Sydney, NSW, AUS, 2021

Website

https://www.regeneus.com.au

Regeneus Ltd is a clinical-stage regenerative medicine company in Australia. It mainly develops a portfolio of cell-based therapies to address unmet medical needs in the human and animal health markets with a focus on osteoarthritis and other musculoskeletal disorders, oncology and dermatology diseases. The company uses stem cell and immuno-oncology technologies to develop cell-based therapies. Its product pipeline consists of two platform technologies, Progenza and Sygenus, across three target therapeutic areas namely osteoarthritis, neuropathic pain, and skin wound healing. The company has one operating segment being the development of innovative cell-based therapies to address significant unmet medical needs in human and veterinary health.

Cambium Bio Headlines

No Headlines